In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

Name: In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?
Uploaded: 2019-03-11T00:00:00+00:00

Created by

Presenter

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader
Professor of Cardiology
University of Adelaide
Consultant Cardiologist
Royal Adelaide Hospital
Adelaide, Australia